Holen Sie sich die Stockscreener-App
213.09
1.44%
-2.61
Handel nachbörslich:
213.00
-0.09
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Picks North Carolina for Campus - Advanced Manufacturing
GE Vernova, Estée Lauder, AbbVie: CNBC's 'Final Trades'AbbVie (NYSE:ABBV), Archer-Daniels-Midland (NYS - Benzinga
AbbVie Inc. stock (US00287Y1091): pharma heavyweight between immunology strength and patent reset - AD HOC NEWS
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool
AbbVie Inc. (ABBV) Stock Analysis: Unraveling a 17% Potential Upside Amid Robust Buy Ratings - DirectorsTalk Interviews
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
AbbVie Expands European Reach As Investors Weigh Dividend Support - Yahoo Finance
Hikari Power Ltd's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026 - Yahoo Finance
First Dallas Securities Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - MSN
KILNER CAPITAL ADVISORS, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - CNBC
Merck (MRK) and AbbVie (ABBV) Gain EU Panel Endorsements for New Treatments - GuruFocus
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval - GuruFocus
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection - Investing News Network
AbbVie, Novartis slash US headcount - PharmaLive
AbbVie receives EU panel backing for Maviret in acute hepatitis C - Investing.com Canada
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection - Yahoo Finance
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market - The Motley Fool
AbbVie to present oncology pipeline data at 2026 ASCO meeting - StreetInsider
ABBV Technical Analysis | Trend, Signals & Chart Patterns | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline - Investing News Network
AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update - AD HOC NEWS
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Investing News Network
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across Its Next-Generation Oncology Pipeline - Moomoo
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval - GuruFocus
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
EU advisers back Allergan’s Boey, a wrinkle shot that works in 8 hours - Stock Titan
Opinion: This program was meant to increase healthcare affordability. The data tell another story. - Crain's Chicago Business
Precision Trading with Abbvie Inc. (ABBV) Risk Zones - Stock Traders Daily
AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength - Yahoo Finance
AbbVie Inc stock (US00287Y1091): new data, dividend strength and oncology focus draw investor attent - AD HOC NEWS
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update - AD HOC NEWS
Three Dividend-Paying Healthcare Giants: Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) Compared for 2026 - Blockonomi
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 - CoinCentral
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update - AD HOC NEWS
Here is what to know beyond why AbbVie Inc. (ABBV) is a trending stock - MSN
AbbVie stock (US00287Y1091): Q1 2026 earnings beat and Skyrizi, Rinvoq drive fresh momentum - AD HOC NEWS
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Pso - GuruFocus
Top 12 Undervalued Dividend Stocks to Buy Now - Insider Monkey
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial - Seeking Alpha
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI - Insider Monkey
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
Neurotoxin Will Generate Booming Growth Opportunities to 2028 | AbbVie, Ipsen Group, Hugel, Inc., Medytox, Inc. etc. - openPR.com
AbbVie stock (US00287Y1091): Q1 2026 earnings highlight Skyrizi and Rinvoq as growth engines - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow - AD HOC NEWS
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit - Law360
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth - TradingView
TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
60,762 Shares in AbbVie Inc. $ABBV Acquired by North Dakota State Investment Board - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC - MarketBeat
AbbVie Inc. (ABBV) Stock Analysis: Unveiling a 20% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
ABBV Stock Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): arthritis drug data and dividend keep the spotlight on the pharma g - AD HOC NEWS
AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Soltis Investment Advisors LLC Acquires 12,096 Shares of AbbVie Inc. $ABBV - MarketBeat
L & S Advisors Inc Has $8.01 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Millennium Capital Advisors LLC Purchases New Shares in AbbVie Inc. $ABBV - MarketBeat
Abacus Wealth Partners LLC Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc stock (US00287Y1091): earnings momentum and pipeline keep big pharma name in focus - AD HOC NEWS
Lawood & Co. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Lockheed Martin Investment Management Co. - MarketBeat
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):